CDMO

Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

Our services include:
1. Process Development
2. Formulation Development
3. Analytical Development
4. Small Scale Biologics / Injectable Production
5. Commercial Scale Injectable Production

6. Dedicated Oncology Production (API / Injectables)
7. Regulatory Affairs

Generic/Peptide/Biosimilar projects available for out-licensing
Oncology-Azacitidine, Bortezomib, Pemetrexed, Fulvestrant
Peptide-Glucagon, Teriparatide, Octreotide, Terlipressin
Biosimilar-Liraglutide, Ranibizumab, Denosumab
Others-Levetiracetam, Palonosetron, Valproate

Interviewee：Dr. Steve J. P. Hsu (President of Genovior Biotech)

CDMO